# idiopathic pulmonary fibrosis (IPF) - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 5217
- Completion tokens: 11844
- Reasoning tokens: 
- Total tokens: 17061
- API requests reported: 
- Elapsed seconds: 21.901
- Final benchmark system: raw; file rank 3/5; original repeat 5; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The provided transcriptomic dataset examines bulk lung tissue gene expression associated with all-cause mortality in idiopathic pulmonary fibrosis (IPF). Analysis of the statistical signal reveals that elevated risk of mortality ($\text{HR} > 1$) is dominated by five interconnected pathogenic themes rather than isolated genetic events:

1. **Aberrant Epithelial Remodeling & Mucociliary Dysfunction:** Co-upregulation of airway mucins, keratins, and surfactant components ($\text{MUC1}$, $\text{MUC21}$, $\text{KRT17}$, $\text{SPRR1A}$, $\text{SFTPB}$, $\text{SFTA2}$, $\text{AGR3}$) reflects progressive loss of normal alveolar type 1/2 cell integrity and expansion of aberrant basaloid/squamoid and bronchioalveolar epithelial populations (honeycombing).
2. **Extracellular Matrix (ECM) Overproduction & Tissue Architecture Remodeling:** High hazard ratios for matrix assembly factors, proteases, and matrix-modifying enzymes ($\text{HTRA1}$, $\text{SPP1}$, $\text{EFEMP1}$, $\text{BMP6}$, $\text{FHL2}$, $\text{MMP25}$, $\text{CHST15}$) capture active fibrogenesis, cross-linking, and focal adhesion dynamics driving loss of lung compliance.
3. **Innate Immune Activation & Myeloid/Neutrophilic Infiltration:** Strong risk associations among neutrophil activation markers ($\text{S100A12}$, $\text{CD177}$, $\text{CXCR1}$), pro-inflammatory chemokines ($\text{CXCL1}$, $\text{CCL7}$, $\text{CXCL14}$), and macrophage clearance/scavenger receptors ($\text{MERTK}$, $\text{STAB1}$) highlight non-resolving innate inflammation as a major correlate of rapid death.
4. **Pro-Survival Receptor Tyrosine Kinase (RTK) Signaling:** Upregulation of growth factors, receptors, and feedback regulators ($\text{HGF}$, $\text{MET}$, $\text{NRG1}$, $\text{SPRY2}$) reflects persistent activation of tissue repair pathways that, in a chronic fibrotic microenvironment, foster disease progression.
5. **Redox Imbalance & Metabolic Adaptation:** Induction of metabolic enzymes and transporters ($\text{SLC7A11}$, $\text{SOD3}$, $\text{ALDH1A3}$, $\text{CYP4F3}$, $\text{STEAP4}$) indicates compensatory responses to severe oxidative stress and cellular lipid/amino acid metabolic stress.

---

### 2. Core Biological Programs

```
                  +-------------------------------------------------------+
                  |  IPF Mortality Risk Transcriptomic Architecture       |
                  +-------------------------------------------------------+
                                              |
        +------------------+------------------+------------------+------------------+
        |                  |                  |                  |                  |
        v                  v                  v                  v                  v
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
| Program 1:    |  | Program 2:    |  | Program 3:    |  | Program 4:    |  | Program 5:    |
| Aberrant      |  | Extracellular |  | Innate Immune |  | RTK & Growth  |  | Cellular      |
| Epithelial    |  | Matrix        |  | Activation &  |  | Factor        |  | Stress &      |
| Remodeling    |  | Remodeling    |  | Myeloid Recr. |  | Signaling     |  | Redox Adapt.  |
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
| MUC1, KRT17,  |  | HTRA1, SPP1,  |  | S100A12,      |  | HGF, MET,     |  | SLC7A11,      |
| SPRR1A, SFTPB |  | BMP6, EFEMP1  |  | CD177, MERTK  |  | NRG1, SPRY2   |  | SOD3, CYP4F3  |
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
```

#### Program 1: Aberrant Airway and Alveolar Epithelial Remodeling
* **Direction:** Associated with increased mortality risk ($\text{HR} > 1$).
* **Supporting Genes:** $\text{MUC1}$ ($\text{HR} = 2.32$), $\text{MUC21}$ ($\text{HR} = 2.10$), $\text{KRT17}$ ($\text{HR} = 2.19$), $\text{SPRR1A}$ ($\text{HR} = 2.28$), $\text{SFTPB}$ ($\text{HR} = 2.66$), $\text{SFTA2}$ ($\text{HR} = 2.25$), $\text{AGR3}$ ($\text{HR} = 2.40$), $\text{PKP3}$ ($\text{HR} = 2.50$), $\text{PRSS8}$ ($\text{HR} = 2.57$), $\text{CEACAM6}$ ($\text{HR} = 2.66$).
* **Standardized Pathway:** Reactome: *Surfactant Metabolism* (R-HSA-5683826) / GO: *Epithelial Cell Differentiation* (GO:0002064).
* **Biological Explanation:** Progressive IPF is characterized by failure of alveolar type 2 ($\text{AT2}$) cells to regenerate normal type 1 ($\text{AT1}$) epithelium, resulting in ectopic expansion of $\text{KRT17}^+/\text{SPRR1A}^+$ basaloid cells and mucous metaplasia ($\text{MUC1}$, $\text{MUC21}$). Simultaneous elevated risk signals from surfactant components ($\text{SFTPB}$, $\text{SFTA2}$) likely represent distorted epithelial cell composition and honeycomb cyst formation in advanced fibrotic tissue.
* **Evidence & Limitations:** Strongly supported by high statistical significance ($P < 10^{-7}$) across multiple independent epithelial markers. Main limitation is bulk transcriptomic confounding: increased hazard ratios may reflect shifts in cellular composition (higher proportion of diseased airway epithelium relative to destroyed normal alveoli) rather than cell-intrinsic transcript upregulation alone.

#### Program 2: Extracellular Matrix Remodeling and Fibrogenic Signaling
* **Direction:** Associated with increased mortality risk ($\text{HR} > 1$).
* **Supporting Genes:** $\text{HTRA1}$ ($\text{HR} = 4.30$), $\text{SPP1}$ ($\text{HR} = 3.40$), $\text{BMP6}$ ($\text{HR} = 3.04$), $\text{EFEMP1}$ ($\text{HR} = 2.33$), $\text{FHL2}$ ($\text{HR} = 2.76$), $\text{MMP25}$ ($\text{HR} = 3.26$), $\text{CHST15}$ ($\text{HR} = 2.99$), $\text{TPST1}$ ($\text{HR} = 2.92$).
* **Standardized Pathway:** Reactome: *Extracellular Matrix Organization* (R-HSA-1474244) / MSigDB Hallmark: *Epithelial-Mesenchymal Transition*.
* **Biological Explanation:** Upregulation of osteopontin ($\text{SPP1}$) and serine protease $\text{HTRA1}$ alongside structural ECM proteins ($\text{EFEMP1}$) and focal adhesion adaptors ($\text{FHL2}$) highlights ongoing active matrix deposition, post-translational sulfation ($\text{CHST15}$, $\text{TPST1}$), and remodeling ($\text{MMP25}$). This program directly captures structural destruction of the lung architecture.
* **Evidence & Limitations:** High hazard ratios (e.g., $\text{HTRA1} = 4.30$, $\text{SPP1} = 3.40$) and strong consistency with established IPF pathophysiology. Limitation: Difficult to determine whether matrix remodeling is a primary driver of death or a downstream marker of total fibrotic burden.

#### Program 3: Innate Immune Activation, Myeloid Dysregulation, and Chemokine Signaling
* **Direction:** Associated with increased mortality risk ($\text{HR} > 1$).
* **Supporting Genes:** $\text{S100A12}$ ($\text{HR} = 2.53$), $\text{CD177}$ ($\text{HR} = 2.72$), $\text{CXCR1}$ ($\text{HR} = 3.28$), $\text{CXCL1}$ ($\text{HR} = 2.99$), $\text{CCL7}$ ($\text{HR} = 3.02$), $\text{CXCL14}$ ($\text{HR} = 2.38$), $\text{MERTK}$ ($\text{HR} = 3.70$), $\text{STAB1}$ ($\text{HR} = 3.29$), $\text{PROK2}$ ($\text{HR} = 3.65$).
* **Standardized Pathway:** KEGG: *Cytokine-Cytokine Receptor Interaction* (hsa04060) / GO: *Neutrophil Activation* (GO:0042119).
* **Biological Explanation:** Innate immune mobilization is marked by neutrophil specific genes ($\text{CD177}$, $\text{S100A12}$, $\text{CXCR1}$) and monocyte/macrophage chemoattractants ($\text{CCL7}$, $\text{CXCL1}$). Concurrently, phagocytic receptor upregulation ($\text{MERTK}$, $\text{STAB1}$) indicates chronic macrophage engagement in clearance of apoptotic cells and matrix turnover. Persistent innate immune drive promotes acute exacerbations and accelerated lung function decline.
* **Evidence & Limitations:** Consistent directionality across chemokines and receptor systems. Limitation: Immune gene signatures in bulk RNA are sensitive to blood contamination and localized microscopic foci of inflammation.

#### Program 4: Receptor Tyrosine Kinase (RTK) and Growth Factor Signaling Loops
* **Direction:** Associated with increased mortality risk ($\text{HR} > 1$).
* **Supporting Genes:** $\text{HGF}$ ($\text{HR} = 2.93$), $\text{MET}$ ($\text{HR} = 2.53$), $\text{NRG1}$ ($\text{HR} = 2.76$), $\text{SPRY2}$ ($\text{HR} = 3.26$).
* **Standardized Pathway:** Reactome: *Signaling by MET* (R-HSA-6800970) / KEGG: *ErbB Signaling Pathway* (hsa04012).
* **Biological Explanation:** Concurrent high hazard ratios for hepatocyte growth factor ($\text{HGF}$) and its receptor ($\text{MET}$), along with neuregulin-1 ($\text{NRG1}$) and Sprouty2 ($\text{SPRY2}$, a negative feedback regulator of receptor tyrosine kinases), demonstrate ongoing pro-survival and tissue repair signaling. In chronic IPF, uncoupled RTK signaling can drive hyperplastic epithelial proliferation and fibromyoblast persistence.
* **Evidence & Limitations:** Validated ligand-receptor pairings present in the dataset. Limitation: HGF/MET signaling has dual roles in lung biology (protective against acute injury vs correlated with severe end-stage disease in clinical cross-sectional cohorts).

#### Program 5: Cellular Stress Response, Metabolic Reprogramming, and Redox Adaptation
* **Direction:** Associated with increased mortality risk ($\text{HR} > 1$).
* **Supporting Genes:** $\text{SLC7A11}$ ($\text{HR} = 3.52$), $\text{SOD3}$ ($\text{HR} = 2.37$), $\text{ALDH1A3}$ ($\text{HR} = 2.27$), $\text{CYP4F3}$ ($\text{HR} = 3.78$), $\text{STEAP4}$ ($\text{HR} = 3.03$), $\text{SLC6A8}$ ($\text{HR} = 3.21$).
* **Standardized Pathway:** GO: *Response to Oxidative Stress* (GO:0006979) / Reactome: *SLC-Mediated Transmembrane Transport* (R-HSA-3247509).
* **Biological Explanation:** Elevated levels of $\text{SLC7A11}$ (the $\text{xCT}$ cystine/glutamate antiporter central to glutathione synthesis and ferroptosis defense), superoxide dismutase 3 ($\text{SOD3}$), lipid/retinoid metabolic enzymes ($\text{CYP4F3}$, $\text{ALDH1A3}$), and metalloreductases ($\text{STEAP4}$) indicate cellular adaptation to intense oxidative stress and metabolic exhaustion in the fibrotic microenvironment.
* **Evidence & Limitations:** Multi-gene representation of metabolic and antioxidant systems. Limitation: Retains association-vs-causation ambiguity—upregulation of antioxidant defenses may represent a futile protective compensatory response to end-stage oxidative tissue destruction.

---

### 3. Key Genes and Interaction Modules

```
      +---------------------------------------------------------------+
      |             Key Functional & Interaction Modules              |
      +---------------------------------------------------------------+

       [HGF] <--- Direct Physical Binding ---> [MET]
         |                                       |
         +-------- (Pathway Co-membership) ------+---> [SPRY2] (Regulatory Feedback)

       [SPP1] <--- Co-expression / Myeloid ---> [MERTK] / [STAB1]
         |
         +-------- (Pathway Co-membership) ---> [HTRA1] / [EFEMP1] (Matrix Remodeling)

       [S100A12] <--- Co-expression (Neutrophil) ---> [CD177] / [CXCR1]

       [KRT17] <--- Co-expression (Epithelial) ---> [SPRR1A] / [MUC1]
```

#### 1. HGF – MET (Growth Factor-Receptor Pair)
* **Statistical Direction:** Both associated with increased mortality ($\text{HGF}$: $\text{HR} = 2.93, P = 9.86 \times 10^{-9}$; $\text{MET}$: $\text{HR} = 2.53, P = 1.84 \times 10^{-8}$).
* **Program Role:** Core components of Program 4 (RTK Signaling).
* **Relationship Type:** **Direct physical interaction** (high-affinity ligand-receptor binding between extracellular HGF and transmembrane MET receptor tyrosine kinase).

#### 2. NRG1 – SPRY2 (RTK Signaling and Feedback Control)
* **Statistical Direction:** Both associated with increased mortality ($\text{NRG1}$: $\text{HR} = 2.76, P = 3.70 \times 10^{-9}$; $\text{SPRY2}$: $\text{HR} = 3.26, P = 2.23 \times 10^{-8}$).
* **Program Role:** Core components of Program 4 (RTK Signaling).
* **Relationship Type:** **Regulatory interaction** (SPRY2 is transcriptionally induced downstream of RTK activation and acts as an intracellular inhibitor of RAS/MAPK signaling).

#### 3. SPP1 (Osteopontin)
* **Statistical Direction:** Associated with increased mortality ($\text{HR} = 3.40, P = 9.77 \times 10^{-8}$).
* **Program Role:** Central node bridging Program 2 (Matrix Remodeling) and Program 3 (Myeloid Activation).
* **Relationship Type:** **Co-expression** and **Pathway co-membership** with macrophage scavenger receptors ($\text{MERTK}$, $\text{STAB1}$) and matrix components ($\text{HTRA1}$). SPP1 is secreted by profibrotic macrophages and acts on integrin/CD44 receptors.

#### 4. HTRA1 (HtrA Serine Peptidase 1)
* **Statistical Direction:** Strongly associated with increased mortality ($\text{HR} = 4.30, P = 7.86 \times 10^{-10}$).
* **Program Role:** Key driver in Program 2 (Matrix Remodeling).
* **Relationship Type:** **Pathway co-membership** with ECM proteins ($\text{EFEMP1}$, $\text{FHL2}$) and **Regulatory interaction** via proteolytic cleavage of extracellular matrix proteoglycans and modulation of TGF-$\beta$ signaling family members.

#### 5. S100A12 – CD177 – CXCR1 (Neutrophil Module)
* **Statistical Direction:** All associated with increased mortality ($\text{S100A12}$: $\text{HR} = 2.53$; $\text{CD177}$: $\text{HR} = 2.72$; $\text{CXCR1}$: $\text{HR} = 3.28$).
* **Program Role:** Core constituents of Program 3 (Innate Immune Activation).
* **Relationship Type:** **Co-expression** (cell-type specific marker co-occurrence in activated polymorphonuclear neutrophils within the lung tissue microenvironment).

#### 6. KRT17 – SPRR1A – MUC1 (Aberrant Epithelial Module)
* **Statistical Direction:** All associated with increased mortality ($\text{KRT17}$: $\text{HR} = 2.19$; $\text{SPRR1A}$: $\text{HR} = 2.28$; $\text{MUC1}$: $\text{HR} = 2.32$).
* **Program Role:** Markers of Program 1 (Epithelial Remodeling).
* **Relationship Type:** **Co-expression** (co-localization in reprogrammed $\text{KRT17}^+/\text{SPRR1A}^+$ basaloid epithelial cells lining fibrotic honeycomb structures).

#### 7. MERTK – STAB1 (Macrophage Clearance Receptors)
* **Statistical Direction:** Both associated with increased mortality ($\text{MERTK}$: $\text{HR} = 3.70, P = 8.05 \times 10^{-9}$; $\text{STAB1}$: $\text{HR} = 3.29, P = 6.51 \times 10^{-8}$).
* **Program Role:** Components of Program 3 (Myeloid Activation).
* **Relationship Type:** **Pathway co-membership** and **Co-expression** (expressed on anti-inflammatory/profibrotic alveolar and tissue-resident macrophages responsible for efferocytosis and scavenger activities).

#### 8. SLC7A11 (Cystine/Glutamate Antiporter xCT)
* **Statistical Direction:** Associated with increased mortality ($\text{HR} = 3.52, P = 1.03 \times 10^{-8}$).
* **Program Role:** Major effector in Program 5 (Redox & Metabolic Adaptation).
* **Relationship Type:** **Pathway co-membership** with oxidative stress handling mechanisms ($\text{SOD3}$) and metabolic processing enzymes ($\text{ALDH1A3}$).

#### 9. MARCKS – BASP1 (Membrane/Cytoskeletal Adaptors)
* **Statistical Direction:** Both associated with increased mortality ($\text{MARCKS}$: $\text{HR} = 4.00, P = 3.63 \times 10^{-8}$; $\text{BASP1}$: $\text{HR} = 3.77, P = 3.07 \times 10^{-8}$).
* **Program Role:** Structural/signaling adaptors involved in cell motility and membrane dynamics across Program 1 and Program 2.
* **Relationship Type:** **Pathway co-membership** (both belong to the actin-filament and PKC-dependent plasma membrane binding protein family regulating cell migration and secretion).

#### 10. CYP4F3 (Leukotriene B4 Omega-Hydroxylase)
* **Statistical Direction:** Associated with elevated mortality ($\text{HR} = 3.78, P = 2.67 \times 10^{-11}$).
* **Program Role:** Metabolic link between Program 3 (Innate Inflammation) and Program 5 (Metabolic Reprogramming).
* **Relationship Type:** **Regulatory interaction** (inactivates pro-inflammatory lipid mediators such as leukotriene B4, acting as an enzymatic control point during neutrophilic pulmonary inflammation).

---

### 4. Validation Priorities

#### Priority 1: Multiplex Spatial Assessment of SPP1+ Macrophages and Matrix Deposition
* **Classification:** Biomarker / Confounding or composition check.
* **Prioritization Rationale:** $\text{SPP1}$ exhibits a very strong hazard ratio ($\text{HR} = 3.40$) and bridges myeloid activation with tissue fibrosis, making it an ideal candidate to assess local fibrotic niche activity.
* **Dataset Evidence:** High statistical significance in bulk RNA transcriptomic survival modeling ($\text{FDR} = 3.99 \times 10^{-5}$).
* **External Evidence:** Single-cell RNA-seq datasets in IPF repeatedly identify a distinct profibrotic $\text{SPP1}^+$ alveolar macrophage population that correlates with disease severity.
* **Next Step for Validation:** Perform multiplex fluorescence *in situ* hybridization (FISH) and spatial transcriptomics on diagnostic IPF lung biopsies to map $\text{SPP1}^+$ macrophage proximity to $\text{HTRA1}^+/\text{EFEMP1}^+$ fibroblasts and structural fibrotic foci.
* **Status:** **Supported hypothesis**.

#### Priority 2: Deconvolution of Aberrant Basaloid Epithelial Signatures ($\text{KRT17}$, $\text{SPRR1A}$, $\text{MUC1}$)
* **Classification:** Confounding or composition check.
* **Prioritization Rationale:** It is critical to determine whether elevated epithelial risk transcripts reflect intrinsic gene activation or simply advanced disease stage (cell-type expansion due to alveolar destruction).
* **Dataset Evidence:** Multiple epithelial differentiation genes ($\text{KRT17}$, $\text{SPRR1A}$, $\text{MUC1}$, $\text{MUC21}$, $\text{PKP3}$) uniformly demonstrate $\text{HR} > 2.0$.
* **External Evidence:** Single-cell atlases demonstrate that $\text{KRT17}^+/\text{SPRR1A}^+$ "aberrant basaloid" cells emerge exclusively in fibrotic lung tissue and occupy the fibroblastic focus interface.
* **Next Step for Validation:** Apply digital cell-type deconvolution algorithms (e.g., CIBERSORTx, Music) using single-cell reference panels on bulk tissue data, followed by single-molecule FISH on tissue sections to evaluate per-cell expression versus cell density.
* **Status:** **Supported hypothesis**.

#### Priority 3: Functional Evaluation of $\text{SLC7A11}$ (xCT) as a Metabolic Vulnerability
* **Classification:** Therapeutic target / Mechanistic hypothesis.
* **Prioritization Rationale:** $\text{SLC7A11}$ is a critical regulator of ferroptosis and redox balance ($\text{HR} = 3.52$). Inhibiting or modulating metabolic adaptation could selectively target persistent fibrotic cells.
* **Dataset Evidence:** Robust positive risk association ($\text{FDR} = 1.09 \times 10^{-5}$) alongside elevated antioxidant genes ($\text{SOD3}$).
* **External Evidence:** Reprogramming of cystine and glutathione metabolism is documented in fibrotic myofibroblasts; however, direct evidence that targeting $\text{SLC7A11}$ alters progression in human lung tissue remains exploratory.
* **Next Step for Validation:** Test $\text{SLC7A11}$ small-molecule inhibitors (e.g., erastin, sulfasalazine) or genetic knockdown in 3D precision-cut lung slices (PCLS) derived from IPF lungs under oxidative challenge to evaluate pro-apoptotic vs pro-fibrotic outcomes.
* **Status:** **Exploratory hypothesis**.

#### Priority 4: Prognostic Utility of Circulating and Tissue Neutrophil Activation Markers ($\text{S100A12}$, $\text{CD177}$)
* **Classification:** Biomarker.
* **Prioritization Rationale:** Neutrophilic markers ($\text{S100A12}$, $\text{CD177}$, $\text{CXCR1}$) show strong hazard ratios ($\text{HR} > 2.5$) and represent accessible protein targets for non-invasive stratification.
* **Dataset Evidence:** Coordinated upregulation of neutrophil chemotactic and activation genes.
* **External Evidence:** Elevated BAL and plasma S100A12 protein levels have been reported to correlate with forced vital capacity (FVC) decline and mortality in independent IPF cohorts.
* **Next Step for Validation:** Measure baseline circulating S100A12 and CD177 protein concentrations via ELISA in a prospective clinical validation cohort of IPF patients and construct multivariable Cox proportional hazards models adjusting for FVC, DLCO, and baseline age.
* **Status:** **Supported hypothesis**.

#### Priority 5: Interrogation of the HGF-MET Signaling Loop and Negative Feedback Regulation ($\text{SPRY2}$)
* **Classification:** Interaction / network hypothesis.
* **Prioritization Rationale:** Concurrent risk association of both ligand ($\text{HGF}$), receptor ($\text{MET}$), and downstream inhibitor ($\text{SPRY2}$) presents a self-contained biological network signal.
* **Dataset Evidence:** Consistent $\text{HR} > 2.5$ for $\text{HGF}$, $\text{MET}$, and $\text{SPRY2}$ with high statistical confidence.
* **External Evidence:** Recombinant HGF displays antifibrotic properties in animal models, whereas elevated tissue/plasma HGF in humans clinically correlates with end-stage disease, creating a therapeutic paradox.
* **Next Step for Validation:** Quantify MET phosphorylation status and SPRY2 protein levels in primary IPF alveolar epithelial cells and fibroblasts subjected to exogenous HGF stimulation to assess whether target tissues develop receptor desensitization or uncoupled signaling.
* **Status:** **Exploratory hypothesis**.

---

### 5. Evidence Grounding

| Major Finding / Biological Node | Direct Input Dataset Evidence | Pathway & Network Evidence | External Literature & Experimental Evidence | Evidence Synthesis & Identified Conflicts |
| :--- | :--- | :--- | :--- | :--- |
| **Aberrant Epithelial Program** ($\text{MUC1}$, $\text{KRT17}$, $\text{SPRR1A}$) | Strongly significant hazard ratios ($\text{HR} = 2.1$–$2.3$, $P < 10^{-7}$) | Enriched in *Surfactant Metabolism* and *Epithelial Differentiation* | Consistently identified in independent single-cell RNA-seq studies of IPF | **Concordant:** Multiple independent marker genes support epithelial reprogramming. However, bulk data cannot separate cell proportion changes from per-cell activation. |
| **Matrix Remodeling & $\text{SPP1}$** | High hazard ratios ($\text{HTRA1} = 4.30$, $\text{SPP1} = 3.40$, $P < 10^{-7}$) | Enriched in *Extracellular Matrix Organization* and *EMT* | $\text{SPP1}$ is an established marker of profibrotic macrophages and disease severity | **Concordant:** Strong cross-validation across literature and input statistics. Truly independent biological evidence from single-cell profiling. |
| **Neutrophil / Myeloid Activation** ($\text{S100A12}$, $\text{CD177}$, $\text{CXCR1}$) | Significant hazard ratios ($\text{HR} = 2.5$–$3.3$, $P < 10^{-7}$) | Enriched in *Cytokine-Cytokine Receptor Interaction* | Elevated blood/BAL neutrophilia correlates with rapid IPF progression | **Concordant:** Pathway and dataset signals agree. Tissue bulk signatures align with clinical biomarker literature. |
| **HGF – MET Signaling Axis** | $\text{HGF}$ ($\text{HR} = 2.93$), $\text{MET}$ ($\text{HR} = 2.53$) | Reactome *Signaling by MET* | Animal models show protective HGF effects; clinical human studies show positive correlation with mortality | **Conflicting / Paradoxical Evidence:** In animal models, HGF delivery is antifibrotic, but in human tissue transcriptomics, high $\text{HGF}/\text{MET}$ is associated with poor survival (likely reflecting severe compensatory induction). |
| **Extreme Numerical Anomalies** | Probes with $\text{HR} = 1.93 \times 10^{-22}$ or $5.18 \times 10^{21}$ ($P = 0$) | Non-informative / Control Probes | Technical artifacts arising from model fitting failures or unnormalized probe sets | **Insufficient Evidence / Technical Error:** Probes such as `CONTROL_A_33_...`, $\text{MIR221}$, $\text{IHH}$, $\text{HCN4}$ reflect numerical overflow/underflow or zero-count errors in Cox modeling and must be excluded from biological interpretation. |

---

### 6. Limitations and Alternative Explanations

1. **Tissue Cell-Composition Artifacts (Deconvolution Ambiguity):** Bulk transcriptomic profiling of diseased lung tissue measures the net average of altered transcript abundance and changing cell-type proportions. In advanced IPF, dense fibrotic scar tissue replaces normal distal airspaces, resulting in an enrichment of profibrotic macrophages ($\text{SPP1}^+$), aberrant basaloid cells ($\text{KRT17}^+$), and matrix-producing myofibroblasts. Thus, elevated hazard ratios may reflect advanced histological progression rather than per-cell hyper-activation of intrinsic death-inducing pathways.
2. **Technical Artifacts and Numerical Model Non-Convergence:** The input data table contains several probe entries with non-physiological hazard ratios ($\text{HR} = 1.93 \times 10^{-22}$ and $\text{HR} = 5.18 \times 10^{21}$) paired with $P = 0$ (e.g., `MIR221`, `CONTROL_A_33_P3222196`, `IHH`, `HCN4`, `FAM75A2`, `OR2M2`). These represent mathematical instability, non-convergence of the Cox proportional hazards regression model (e.g., Hauck-Donner effect or complete separation), or improper handling of control probes. Biological conclusions must not be drawn from these specific entries.
3. **Disease Stage and Severity Confounding:** Biopsies or tissue samples obtained from patients at later stages of disease will inherently over-represent inflammatory, metabolic, and matrix-remodeling signatures. Consequently, transcriptomic features associated with end-stage tissue destruction will correlate with all-cause mortality primarily as secondary markers of functional impairment (e.g., severely reduced baseline FVC or DLCO) rather than as primary causative drivers of disease progression.
4. **Unadjusted Clinical Covariates and Treatment Exposure:** The survival analysis lacks explicit adjustment for essential clinical parameters, including patient age, sex, smoking history, baseline lung function metrics, and concurrent antifibrotic pharmacotherapy (e.g., pirfenidone or nintedanib). Immunomodulatory treatments or antifibrotic therapies can significantly alter metabolic and cytokine transcript profiles, potentially distorting observed prognostic associations.
5. **Association vs. Causation Ambiguity (Compensatory Signaling):** Elevated hazard ratios for protective or compensatory pathways—such as antioxidant defenses ($\text{SOD3}$) or tissue regenerative ligands ($\text{HGF}$)—create an analytical paradox. These genes may be strongly upregulated in non-survivors as a downstream, futile host attempt to counter extensive oxidative injury and alveolar damage, leading unadjusted statistical models to misclassify them as "risk-associated" factors.
